LINC00858: A Potential Drug Target and Biomarker (G170425)

Target Name: LINC00858

NCBI ID: G170425

LINC00858

Other Name(s): CRCAL-2 | long intergenic non-protein coding RNA 858 | Long intergenic non-protein coding RNA 858

LINC00858: A Potential Drug Target and Biomarker

LINC00858 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the myeloid-specific gene expression and has been shown to play a role in the development and maintenance of various diseases, including cancer.

The discovery of LINC00858 as a potential drug target and biomarker was made by a team of researchers at the University of California, San Diego. The researchers used a variety of techniques, including RNA sequencing and bioinformatics analysis, to identify the molecule's unique characteristics and its potential as a drug target.

One of the key findings of the study was that LINC00858 was highly expressed in various tissues and was significantly downregulated in cancer tissues compared to non-cancerous tissues. This suggests that LINC00858 may be a useful biomarker for detecting cancer and evaluating the effectiveness of cancer treatments.

In addition to its potential as a drug target, LINC00858 has also been shown to have a number of potential biomarker properties. For example, the researchers found that LINC00858 was significantly downregulated in patient samples from various types of cancer, including breast, lung, and colorectal cancers. This suggests that LINC00858 may be a useful biomarker for detecting the spread of cancer and evaluating the effectiveness of cancer treatments.

Another potential application of LINC00858 as a drug target is its role in the regulation of cellular processes that are relevant to a wide range of diseases, including cancer. The researchers found that LINC00858 was involved in the regulation of cell adhesion, a critical process that is involved in the development and maintenance of tissues and organs. This suggests that LINC00858 may be a useful target for drugs that are designed to inhibit cell adhesion and promote the development of cancer.

Overall, the discovery of LINC00858 as a potential drug target and biomarker has significant implications for the development of new cancer treatments. Further research is needed to fully understand the molecule's role in the development and progression of cancer, as well as its potential as a biomarker for detecting cancer.

Protein Name: Long Intergenic Non-protein Coding RNA 858

The "LINC00858 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00858 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets